For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

Shares of Novo Nordisk NVO gained 2.8% on Wednesday likely because the analysts at UBS upgraded the company’s rating from ...

Madrigal Pharmaceuticals' strong launch is confirmed with impressive sales in Q1 and Q2. Learn why MDGL stock could benefit ...

This is the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and ...

At her Thanksgiving table in 2024, half of Ashley Dunham's guests were on a GLP-1 weight loss drug. She made green beans for ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not ...

Weight management platform Found is today launching oral semaglutide dissolvable tablets for individuals looking for ...

Novo Nordisk initiated study validates the power of proteomics to provide unique insights into mechanisms of action and ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...